Advertisement

Topics

DNX-2401 Demonstrates "Dramatic" Survival Benefit in Glioma

10:32 EST 15 Feb 2018 | OncLive

Treatment with the investigational agent DNX-2401 resulted in 20% of a cohort of patients with recurrent malignant glioma surviving more than 3 years from the time of treatment. 

Original Article: DNX-2401 Demonstrates "Dramatic" Survival Benefit in Glioma

NEXT ARTICLE

More From BioPortfolio on "DNX-2401 Demonstrates "Dramatic" Survival Benefit in Glioma"

Advertisement
Quick Search
Advertisement
Advertisement